SAR650984 with Lenalidomide, Dexamethasone Induces Responses in Multiple Myeloma
Multiple myeloma treated with SAR650984 in combination with lenalidomide/dexamethasone see clinical benefit rate (CBR) of 65%.
Multiple myeloma treated with SAR650984 in combination with lenalidomide/dexamethasone see clinical benefit rate (CBR) of 65%.
Isolated testicular relapse in children with acute lymphoblastic leukemia (ALL) is associated with improved outcomes.
Disruption of tunneling nanotubules reduces the survival benefit that mesenchymal cells provide to primary acute lymphoblastic leukemia (ALL).
Adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma is clinically meaningful for progression-free survival.
The top inherited genetic loci are likely linked with the development of asparaginase hypersensitivity.
Ofatumumab maintenance provided clinically meaningful benefits for patients with relapsed chronic lymphocytic leukemia (CLL).
Fludarabine, cyclophosphamide, and rituximab (FCR) remains standard of care in very fit patients with chronic lymphocytic leukemia (CLL).
Minimal residual disease (MRD) negativity with clinical response predicts progression-free survival (PFS) in chronic lymphocytic leukemia (CLL).